The deal implies a valuation of $4.76 billion for Theravance's future royalty income from the four-product franchise, which suggests that the market considerably undervalues the South San Francisco-based biotech firm

The deal implies a valuation of $4.76 billion for Theravance's future royalty income from the four-product franchise, which suggests that the market considerably undervalues the South San Francisco-based biotech firm

San Francisco) Cometriq Cabozantinib Castration-resistant prostate cancer Bone metastases showed a 67% rate of bone scan response and other clinical signs of effect 4/12/13 Onconova Therapeutics Inc. (Newtown, Pa.) Rigosertib A dual pathway inhibitor Solid tumors Phase I data showed tolerability and favorable antitumor activity 4/11/13 Pharmacyclics Inc. (Sunnyvale, Calif.) Ibrutinib Oral agent Chronic lymphocytic leukemia Phase II data showed that 95% of patients experienced a reduction in

San Francisco) Zybrestat Antiangiogenic therapeutic

South San Francisco-based Theravance's shares (NASDAQ:THRX) jumped 11.6 percent on news from the FDA, closing Friday at $34.94, up $3.63

Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco

San Francisco) CK-2127107 Molecule activator of the fast skeletal muscle troponin complex Conditions associated with neuromuscular dysfunction, muscular weakness and/or muscle fatigue Started a Phase I trial 4/2/13 Immunomic Therapeutics Inc. (Lancaster, Pa.) JRC-LAMP-vax Immunothera-peutic vaccine Red cedar allergy Phase I data showed it met all of its primary safety endpoints 4/25/13 Lipocine Inc. (Salt Lake City) LPCN 1111 Next-generation oral testosterone replacement product Testosterone

Company (Location) Product Description Indication Status Date AUTOIMMUNE Rigel Pharmaceuticals Inc. (South San Francisco) and AstraZeneca plc (London) Fostamatinib Oral spleen tyrosine kinase inhibitor Rheumatoid arthritis Missed the X-ray endpoint of modified Total Sharp score, but hit statistical significance in ACR20 scoring, although the Phase III still fell short of those achieved by Pfizer Inc.'s approved Xeljanz 4/8/13 CANCER Array BioPharma Inc. (Boulder, Colo.) ARRY-520 A selective KSP

Curis earned a $4 million milestone payment from Genentech Inc., of South San Francisco (a unit of Roche AG), as a result of the Australian approval

once-daily Multiple sclerosis Was approved in Argentina in a 14 mg formulation for patients with relapsing forms 4/9/13 CANCER Celgene Corp. (Summit, N.J.) Revlimid Lenalidomide Transfusion-dependent anemia CHMP adopted a positive opinion for Revlimid 4/29/13 Curis Inc. (Lexington, Mass.) Erivedge Vismodegib Symptomatic metastatic basal cell carcinoma CHMP recommended conditional approval 4/29/13 Medivation Inc. (San Francisco) and Astellas Pharma Inc. (Tokyo) Xtandi Enzalutamide Metastatic

San Francisco) and GlaxoSmithKline plc (London) Breo Fluticasone furoate (FF)/vilanterol (VI), the combination corticosteroid and long-acting beta2 agonist Chronic obstructive pulmonary disease FDA committee recommended approval 4/18/13 Tris Pharma Inc. (Monmouth Junction, N.J.) Karbinal ER Carbinoxamine maleate extended-release oral suspension Seasonal and perennial allergic rhinitis FDA approved it 4/4/13 MISCELLANEOUS Enlivex Therapeutics Ltd. (Jerusalem) ApoCell A treatment based on inducing

Jennerex Biotherapeutics Inc., of San Francisco, said the FDA granted orphan drug status for Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of hepatocellular carcinoma (HCC

Exelixis Inc. , of South San Francisco, reported net revenues for the quarter ended March 31, 2013, were $9.7 million, compared to $18.5 million for the comparable period in 2012...Onyx Pharmaceuticals Inc. , of South San Francisco, reported a doubling of its total revenues to $145.5 million in its financial results for the first quarter 2013, as compared to total revenue of $72 million for the comparable period in 2012

Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers

SAN FRANCISCO – When AiCuris GmbH, of Wuppertal, Germany, analyzed the market for human cytomegalovirus (HCMV) therapies, it found a market with high medical need, neglected by big pharma, featuring a variety of disease manifestations...Rubsamen-Schaeff accepted the award on behalf of AiCuris at an award banquet recently at the Palace Hotel in San Francisco

VistaGen Therapeutics Inc., of South San Francisco, said its human pluripotent stem cell-derived cardiomyocytes were used by collaboration partner Duke University to grow three-dimensional (3D) human heart muscle

Portola Pharmaceuticals Inc., of South San Francisco, set the price range for its proposed initial public offering (IPO), aiming to sell 6.9 million shares priced between $13 and $16 each

And More Check out BioWorld Today's coverage of Allicense 2013 held in San Francisco last week

LLC acted as exclusive placement agent 4/19/13 Ohr Pharmaceutical Inc. (New York) Exercise of Series B warrants N/A $5.05 Ohr raised about $5.05M from institutional and accredited shareholders through the exercise of Series B warrants 4/23/13 OxiGene Inc. (South San Francisco) Private placement of zero coupon convertible preferred stock Convertible into 1.38S $5 OxiGene raised $5M through the placement...StemCells issued SVB a warrant to purchase 293,531 shares of common stock at $1.7034 per share